Positive top-line results from MYRROR trial of Eylea (Regeneron/Bayer HealthCare) for Choroidal Neovascularization
Top-line results for Eylea (aflibercept), from Bayer HealthCare and Regeneron, in the Phase III MYRROR study in myopic Choroidal Neovascularization (mCNV) show benefit for patients. In this trial, patients receiving Eylea at an initial dose of 2 milligrams (mg), followed by treatment on an as-needed (PRN) basis, had a mean improvement in best-corrected visual acuity (BCVA) from baseline at week 24 of 12.1 letters, compared to a loss of 2.0 letters in patients receiving sham injections (p<0.0001). the most common adverse events observed in the myrror trial that occurred with a frequency of 2% or more were conjunctival hemorrhage, dry eye, eye pain, headache and nasopharyngitis.>
Data from this study will be presented at an upcoming medical conference. Bayer HealthCare expects to submit the first application for regulatory approval for this indication in Asia in the second half of 2013.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins